Karen Pendergrass

Karen Pendergrass, Standards Team

About

Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.

Recent Posts

2025-05-17

Associations Between Endometriosis and Gut Microbiota

This study examines the association between endometriosis and gut microbiota, highlighting significant differences in microbial diversity and composition. Women with endometriosis showed altered gut microbial profiles compared to healthy controls, with specific bacterial shifts linked to gastrointestinal symptoms and hormonal therapy. These findings suggest microbiota-targeted therapies may benefit endometriosis management.

2025-04-27

Exploration of the Relationship Between Gut Microbiota and Polycystic Ovary Syndrome (PCOS)

This review links gut microbiota disruption to the development and symptoms of PCOS, including insulin resistance and hyperandrogenism. It highlights microbiota-targeted therapies—like probiotics, prebiotics, and traditional medicine—as promising options to improve PCOS outcomes and repositions the gut microbiome as a central factor in understanding and treating the disorder.

2025-04-25

How Severe Anemia Might Influence the Risk of Invasive Bacterial Infections in African Children

This review investigates the hypothesis that severe anemia contributes to the elevated risk of invasive bacterial infections in African children through dysregulation of iron homeostasis, including the disruption of hepcidin—a hepatic hormone that governs iron availability in the body. The authors synthesize evidence from epidemiological, mechanistic, and experimental studies, proposing that the […]

2025-04-21

Vaginal Microbiome Transplant (VMT)

Vaginal Microbiome Transplant (VMT) involves transferring healthy vaginal flora from a donor to a recipient to treat conditions like recurrent bacterial vaginosis. It aims to restore balance in the vaginal microbiome, potentially offering a non-pharmacological treatment option for persistent gynecological disorders.

2025-03-22

Facultative Anaerobes

Facultative anaerobes are microorganisms—primarily bacteria—that possess the metabolic flexibility to grow in both the presence and absence of oxygen.

2025-03-19

Type 1 Diabetes

Copper dysregulation plays a definitive role in the pathogenesis of Type 1 Diabetes Mellitus (T1DM). Elevated copper levels increase the risk of developing T1DM by 15-fold per standard deviation, highlighting copper’s critical influence on oxidative stress and inflammatory pathways central to the disease. Studies show that T1DM patients exhibit higher copper levels and […]

2025-03-19

Microbiota-targeted interventions for mental health

This review explores microbiota-targeted interventions for mental health, including probiotics, prebiotics, synbiotics, FMT, and diet. While promising, large-scale trials are needed to refine evidence-based strategies. Microbiota-based therapies may serve as adjuncts for psychiatric care, highlighting the gut-brain axis as a key target for future research.

2025-03-18

Transvaginal Photobiomodulation for the Treatment of Chronic Pelvic Pain: A Pilot Study

The study in question focused on the use of transvaginal photobiomodulation (TV-PBM) as a treatment for chronic pelvic pain (CPP) in women. Here are the details based on the key aspects of the study: What was studied? The research investigated whether transvaginal photobiomodulation could effectively reduce chronic pelvic pain in women. This was a […]

2025-03-18

TMAO: how gut microbiota contributes to heart failure

This review underscores the critical role of gut microbiota and TMAO in heart failure pathophysiology and opens up new avenues for therapeutic interventions targeting the gut–TMAO–HF axis. The findings suggest promising directions for future research and clinical applications aimed at improving HF patient care and outcomes.

2025-03-18

The Role of the Microbiome in Erectile Dysfunction: A review

This review discusses the increasingly recognized role of the human microbiome in health and disease, particularly focusing on its implications for erectile dysfunction (ED). The review highlights several key points: Evidence Linking Microbiome to ED Risk Factors: There is compelling evidence associating the gut microbiome with conditions known to contribute to ED, including diabetes, hypertension, […]

2025-03-18

The Revaluation of Plant-Derived Terpenes to Fight Antibiotic-Resistant Infections

The study focused on terpenes derived from plants as potential antimicrobial agents, particularly their effectiveness against antibiotic-resistant infections. This included an exploration of the diverse mechanisms by which terpenes combat microbial resistance, their bioavailability, and the synergistic effects when combined with other antimicrobials. Who was studied? The research mainly involved microbial […]